Small Cell Lung Cancer (SCLC)

The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.

The addition of socazolimab to carboplatin plus etoposide was well tolerated compared with placebo in patients with extensive-stage small cell lung cancer.

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Safety and efficacy were noted with LB2102 for patients with small cell lung cancer and large cell neuroendocrine carcinoma.

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild to moderate severity.

The safety profile of camrelizumab plus apatinib and chemotherapy in a phase 1 study aligns with prior reports of each agent.

The phase 3 IMforte trial evaluating lurbinectedin plus atezolizumab is the first to show PFS and OS improvement with first-line maintenance for ES-SCLC.

Here are 3 things you should know about the multimodal treatment of patients with SCLC.

No new safety signals were observed with bevacizumab, atezolizumab, carboplatin, and etoposide in extensive-stage small cell lung cancer.

Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.

Data may support anlotinib/benmelstobart plus chemotherapy as a preferable frontline treatment option in extensive-stage small cell lung cancer.

Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.

Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.

Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Patient-reported adverse effects associated with tarlatamab appeared to be generally mild in the phase 2 DeLLphi-301 trial.

The safety profile for tarlatamab was consistent with its known profile in patients with relapsed small cell lung cancer.

Real-world data may support a new way to consider follow-up treatment for patients who are older with extensive-stage small cell lung cancer.

Investigators will assess the safety, pharmacology, and maximum tolerated dose of ST-001 in relapsed/refractory SCLC as part of a phase 1a/1b trial.

Tislelizumab plus chemotherapy demonstrated superior OS, PFS, ORR, and DOR results compared with placebo plus chemotherapy in first-line ES-SCLC.

Intravenous olvi-vec demonstrated a manageable safety and tolerability profile consistent with previous trials evaluating the investigational agent.

Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.

Real-world atezolizumab plus chemotherapy data demonstrated similar efficacy compared with what the phase 3 IMpower133 trial showed.

In patients with small cell lung cancer, Lambert-Eaton myasthenic syndrome leads to muscle weakness and can be discovered with no-cost testing such as anti-VGCC antibody testing.